AR105224A1 - Anticuerpos monoclonales humanos dotados de fuerte actividad neutralizadora contra los virus herpes simple tipo 1(hsv-1) y tipo 2 (hsv-2) - Google Patents
Anticuerpos monoclonales humanos dotados de fuerte actividad neutralizadora contra los virus herpes simple tipo 1(hsv-1) y tipo 2 (hsv-2)Info
- Publication number
- AR105224A1 AR105224A1 ARP160100219A ARP160100219A AR105224A1 AR 105224 A1 AR105224 A1 AR 105224A1 AR P160100219 A ARP160100219 A AR P160100219A AR P160100219 A ARP160100219 A AR P160100219A AR 105224 A1 AR105224 A1 AR 105224A1
- Authority
- AR
- Argentina
- Prior art keywords
- type
- hsv
- monoclonal antibodies
- seq
- human monoclonal
- Prior art date
Links
- 241000701074 Human alphaherpesvirus 2 Species 0.000 title abstract 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se encuentra en el campo de los anticuerpos monoclonales aptos para la inmunoterapia pasiva de infecciones causadas por el virus del herpes simple tipo 1 y tipo 2 (HSV-1 y HSV-2) y se relaciona con anticuerpos monoclonales humanos o fragmentos de tales anticuerpos, que se unen y neutralizan el virus del herpes simple tipo 1 y tipo 2 y su utilización en la profilaxis o tratamiento de enfermedades vinculadas a los virus del herpes simple tipo 1 y tipo 2. Reivindicación 1: Un anticuerpo monoclonal, o su fragmento, que se une al virus del herpes simple de tipo 1 y de tipo 2, que comprende una región variable en la cadena pesada (VH) y en la cadena liviana (VL). Dicho anticuerpo, o fragmento de anticuerpo, comprende una región determinante de la complementariedad (CDR, en inglés) seleccionada del grupo que consta de SEQ ID Nº 3, SEQ ID Nº 6, SEQ ID Nº 9 y SEQ ID Nº 12.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152909.6A EP3050897A1 (en) | 2015-01-28 | 2015-01-28 | Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105224A1 true AR105224A1 (es) | 2017-09-20 |
Family
ID=52396596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100219A AR105224A1 (es) | 2015-01-28 | 2016-01-27 | Anticuerpos monoclonales humanos dotados de fuerte actividad neutralizadora contra los virus herpes simple tipo 1(hsv-1) y tipo 2 (hsv-2) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10626167B2 (es) |
| EP (2) | EP3050897A1 (es) |
| JP (1) | JP6825784B2 (es) |
| CN (1) | CN108064239B (es) |
| AR (1) | AR105224A1 (es) |
| MA (1) | MA41775A (es) |
| TW (1) | TW201639882A (es) |
| UY (1) | UY36540A (es) |
| WO (1) | WO2016120410A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45788A (fr) | 2016-07-26 | 2019-06-05 | Polichem Sa | Activité synergique anti-hsv d'anticorps et d'agents antiviraux |
| WO2020041911A1 (es) | 2018-08-28 | 2020-03-05 | Pontificia Universidad Catolica De Chile | Anticuerpo monoclonal 11b2c7 o fragmento del mismo, que reconoce específicamente virus herpes simple 1 y 2 |
| US12247066B2 (en) | 2018-08-28 | 2025-03-11 | Pontificia Universídad Católica de Chile | Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US77678A (en) * | 1868-05-05 | Improved lifting-jack | ||
| US5646041A (en) | 1987-02-12 | 1997-07-08 | Harfeldt; Elisabeth | Monoclonal antibody to herpes simplex virus and cell line producing same |
| WO1995018634A1 (en) * | 1994-01-04 | 1995-07-13 | The Scripps Research Institute | Human monoclonal antibodies to herpes simplex virus and methods therefor |
| JP2001501101A (ja) | 1996-10-01 | 2001-01-30 | メルク エンド カンパニー インコーポレーテッド | ポリヌクレオチドヘルペスウイルスワクチン |
| US8252906B2 (en) * | 2009-01-05 | 2012-08-28 | Dcb-Usa Llc | Anti-herpes simplex virus antibodies and methods of use thereof |
| ES2395746T3 (es) | 2009-05-04 | 2013-02-14 | Ribovax Biotechnologies Sa | Fragmentos de enlace de antigeno de un anticuerpo para utilizar en el tratamiento y diagnóstico de enfermedades oculares |
| EP2308895A1 (en) * | 2009-10-01 | 2011-04-13 | Universität Duisburg-Essen | Anti-HSV antibody |
-
2015
- 2015-01-28 EP EP15152909.6A patent/EP3050897A1/en not_active Withdrawn
-
2016
- 2016-01-26 UY UY0001036540A patent/UY36540A/es unknown
- 2016-01-27 TW TW105102484A patent/TW201639882A/zh unknown
- 2016-01-27 MA MA041775A patent/MA41775A/fr unknown
- 2016-01-27 AR ARP160100219A patent/AR105224A1/es unknown
- 2016-01-28 CN CN201680019176.9A patent/CN108064239B/zh not_active Expired - Fee Related
- 2016-01-28 WO PCT/EP2016/051844 patent/WO2016120410A1/en not_active Ceased
- 2016-01-28 US US15/546,422 patent/US10626167B2/en not_active Expired - Fee Related
- 2016-01-28 EP EP16705043.4A patent/EP3271386A1/en not_active Withdrawn
- 2016-01-28 JP JP2017540645A patent/JP6825784B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6825784B2 (ja) | 2021-02-03 |
| US10626167B2 (en) | 2020-04-21 |
| MA41775A (fr) | 2018-01-23 |
| EP3271386A1 (en) | 2018-01-24 |
| EP3050897A1 (en) | 2016-08-03 |
| TW201639882A (zh) | 2016-11-16 |
| CN108064239A (zh) | 2018-05-22 |
| UY36540A (es) | 2016-08-31 |
| US20180009879A1 (en) | 2018-01-11 |
| JP2018505181A (ja) | 2018-02-22 |
| CN108064239B (zh) | 2021-11-02 |
| WO2016120410A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| AR132864A2 (es) | UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| ECSP18043564A (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| CO2017005738A2 (es) | Anticuerpos anti-pd-1 | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| CU24597B1 (es) | Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20 | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| EA201591973A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| EA201890578A1 (ru) | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| AR119507A1 (es) | Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3 | |
| CO2018000652A2 (es) | Anticuerpo anti-epha4 | |
| MX2016008794A (es) | Secuencias de anticuerpos especificos para e. coli. | |
| MX2019010339A (es) | Anticuerpos neutralizadores de flavivirus y metodos de uso de los mismos. | |
| CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| AR105224A1 (es) | Anticuerpos monoclonales humanos dotados de fuerte actividad neutralizadora contra los virus herpes simple tipo 1(hsv-1) y tipo 2 (hsv-2) | |
| AR115192A1 (es) | Anticuerpos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |